| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From TNO Quality of Life, Business Unit BioSciences, Zeist, Netherlands (EB); the Institute National de la Recherche Agronomique, GROUPE Ostéoporose, Saint-Genès Champanelle, France (BC); the Rowett Research Institute, Bucksburn, Aberdeen, United Kingdom (SR); the Laboratory of Organic Chemistry, Department of Chemistry, University of Helsinki, Helsinki, Finland (KW); the School of Medicine, University of East Anglia, Norwich, United Kingdom (AC); and the National Institute for Research on Food and Nutrition, Human Nutrition Unit, Rome, Italy (FB)
Background: Osteoporosis is a major health problem. It was hypothesized that isoflavone-containing products may be a potential alternative to hormone replacement therapy for preventing bone loss during the menopausal transition.
Objective: The objective was to investigate whether the consumption of isoflavone-enriched foods for 1 y affects bone mineral density, bone metabolism, and hormonal status in early postmenopausal women.
Design: This was a randomized, double-blind, placebo-controlled, parallel, multicenter trial. Two hundred thirty-seven healthy early postmenopausal women [mean (±SD) age of 53 ± 3 y and time since last menses of 33 ± 15 mo] consumed isoflavone-enriched foods providing a mean daily intake of 110 mg isoflavone aglycones or control products for 1 y while continuing their habitual diet and lifestyle. Outcome measures included bone mineral density of the lumbar spine and total body, markers of bone formation and bone resorption, hormones, isoflavones in plasma and urine, safety variables, and adverse events.
Results: Consumption of isoflavone-enriched products did not alter bone mineral density of the lumbar spine and total body or markers of bone formation and bone resorption. Hormone concentrations did not differ between the isoflavone and control groups. Consumption of isoflavone-enriched products resulted in increased isoflavone concentrations in plasma and urine, whereas control products did not. This finding indicated good compliance with treatment. Subgroup analysis did not support an effect of equol phenotype on bone density. The intervention had no effect on a range of safety variables and reported adverse events.
Conclusion: Consumption of foods containing 110 mg/d of soy isoflavone aglycone equivalents for 1 y did not prevent postmenopausal bone loss and did not affect bone turnover in apparently healthy early postmenopausal white women. This trial was registered at clinicaltrials.gov as NCT00301353.
Key Words: Isoflavones • bone mineral density • menopause • hormones
This article has been cited by other articles:
|
|
 |
|
  W. W Wong, R. D Lewis, F. M Steinberg, M. J Murray, M. A Cramer, P. Amato, R. L Young, S. Barnes, K. J Ellis, R. J Shypailo, et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial Am. J. Clinical Nutrition, November 1, 2009; 90(5): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M Kenny, K. M Mangano, R. H Abourizk, R. S Bruno, D. E Anamani, A. Kleppinger, S. J Walsh, K. M Prestwood, and J. E Kerstetter Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial Am. J. Clinical Nutrition, July 1, 2009; 90(1): 234 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hooper, J.J. Ryder, M.S. Kurzer, J.W. Lampe, M.J. Messina, W.R. Phipps, and A. Cassidy Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis Hum. Reprod. Update, July 1, 2009; 15(4): 423 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W Lampe Is equol the key to the efficacy of soy foods? Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1664S - 1667S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
